Versant Ventures Overview
- Investor Type
-
Venture Capital
- Status
-
Active
- Professionals
-
25
- Investments
-
473
- Portfolio
-
53
- Exits
-
212
Versant Ventures General Information
Description
Founded in 1999, Versant Ventures is a venture capital firm based in San Francisco, California. The firm seeks to invest in the manufacturing, life sciences, oncology, industrials, impact investing, and pharmaceuticals sectors.
Contact Information
Website
versantventures.com
Year Founded
1999
Investor Status
Actively Seeking New Investments
Trade Association
Canadian Venture Capital and Private Equity (CVCPE)
National Venture Capital Association (NVCA)
Primary Investor Type
Venture Capital
Other Investor Types
Accelerator/Incubator
Primary Office
- One Sansome Street
- Suite 3630
- San Francisco, CA 94104
- United States
+1 (415) 000-0000
Versant Ventures Investments (473)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Company Stage | Lead Partner |
|---|---|---|---|---|---|---|
| Belharra Therapeutics | 04-Jan-2023 | Early Stage VC | 0000 | Drug Delivery | Generating Revenue | 000000 0000000 00.0 |
| 000000000 00000000 | 09-Dec-2022 | 00000 00000 | 0000 | Drug Discovery | Generating Revenue | 000000000 000000 00.0 |
| 0000 000000000000 | 22-Nov-2022 | 00000 00000 | 0000 | Drug Discovery | Generating Revenue | 00000 00000 00.0 |
| 000000 | 21-Nov-2022 | 00000 00000 | 0000 | Drug Discovery | Pre-Clinical Trials | 000000 0000000 00.0 |
| 00000 000000000000 | 15-Nov-2022 | 00000 00000 | 00000 | Drug Discovery | Pre-Clinical Trials | 00000 0000000 00.0 |
| 0000 000000000000 | 15-Nov-2022 | 00000 00000 | 0000 | Biotechnology | Stealth | 00000 0000000 00.0 |
| 000000 00000000000 | 06-Oct-2022 | 00000 00000 | 0000 | Drug Discovery | Clinical Trials - Phase 2 | 00000 0000000 00.0 |
| 00000 000000000000 | 12-Sep-2022 | 00000 00000 | 000.00 | Biotechnology | Startup | |
| Vector Biopharma | 10-Aug-2022 | Early Stage VC | 0000 | Discovery Tools (Healthcare) | Startup | 000000000 000000 00.0 |
| Tempest Therapeutics | 29-Apr-2022 | PIPE | 0000 | Drug Discovery | Generating Revenue | 000000 0000000 00.0 |
Versant Ventures Exits (212)
| Company Name | Exit Date | Exit Type | Exit Size |
|---|---|---|---|
| Akero Therapeutics | 17-Jun-2022 | Secondary Transaction - Open Market | 0000 |
| 0000000 0000000000 | 24-Mar-2022 | 000 00 00000000 | |
| 0000000 | 07-Jan-2022 | 000000000000000000 | 00000 |
| 0000000 (000000000 | 26-Oct-2021 | 000 | 0000 |
| 000 0000000 | 01-Oct-2021 | 000000000 00000000 | |
| 00000 | 29-Sep-2021 | 0000000000: 000000 | |
| 00000000 000000000 | 01-Aug-2021 | 000000000000000000 | 00.00 |
| 0000000 000000 | 01-Jul-2021 | 000000000 00000000 | |
| Tempest Therapeutics | 28-Jun-2021 | Reverse Merger | |
| Graphite Bio | 25-Jun-2021 | IPO | 00000 |
Versant Ventures Fund Performance
| Fund Name | Vintage | Size | Dry Powder | DPI | RVPI | TVPI | IRR |
|---|
Versant Ventures Investments by Industry, Year, and Region
Investments by Industry
Investments by Year
Investments by Region
Versant Ventures Team (68)
| Name | Title | Deals | Funds | Boards | Office |
|---|---|---|---|---|---|
| Charles Warden | Co-Founder and Managing Director | 00 | 0 | 0 | San Francisco, CA |
| Barbara Lubash | Co-Founder & Managing Director | 00 | 0 | 0 | San Francisco, CA |
| Donald Milder | Co-Founder & Managing Director | 0 | 0 | 0 | San Francisco, CA |
| Rebecca Robertson | Co-Founder & Managing Director | 00 | 0 | 0 | San Francisco, CA |
| Ross Jaffe MD | Co-Founder & Managing Director | 00 | 0 | 0 | San Francisco, CA |
Versant Ventures Co-Investors (177)
| Name | With | Exits | Lead Partner | Series | Industry |
|---|---|---|---|---|---|
| OrbiMed | 11 | 0 | 0 |
|
|
| RA Capital Management | 00 | 0 | 00 |
|
|
| Logos Capital | 0 | 0 | 0 |
|
|
| New Enterprise Associates | 0 | 0 |
|
|
|
| Casdin Capital | 0 | 0 | 0 |
|
|